To the Editor: Drug-induced liv--er injury is a potential complication of many medications. Montelukast and zafirlukast are competitive and selective leukotriene-receptor an--tagonists (LTRA) approved for the prophylaxis and chronic treatment of asthma in pediatric patients and adults. These LTRA are usu--ally well tolerated. Montelukast is extensively metabolized by the he--patic microsomal cytochrome P450 3A4 and 2C9. 1 Hepatotoxicity has been associated with not only zafir--lukast, but recent reports have also described elevated liver enzyme levels, hepatitis, and fulminant he--patic failure induced by montelu--kast. [2] [3] [4] [5] [6] [7] [8] However, all the described cases are adult patients and there have been no similar reports with montelukast in children. We pres--ent a patient who we believe is the first pediatric case of acute hepati--tis while receiving montelukast.
A 5-year-old boy was admitted to our hospital with fatigue, nau--sea, vomiting and abdominal pain. The patient had a history of chron--ic bronchial asthma. He had been prescribed montelukast at a 5 mg daily dose for the last 2 years. On physical examination, he was not ic--teric, the abdomen was nontender, and no hepatosplenomegaly or as--cites were present. Examination of other systems were normal. At presentation, the aspartate amino--transferase (AST) level was 990 IU/L (normal, 15 to 55 IU/L), the alanine aminotransferase (ALT) level was 658 IU/L (normal, 5 to 45 IU/L), the glutamyltranspepti--dase level was 145 IU/L (normal, 5 to 32 IU/L), the total bilirubin level was 2.8 mg/dL, the indirect 0.7 mg/dL, the direct 2.1 mg/dL, Probable montelukastinduced hepatotoxicity in a pediatric patient: case report and the ALP level was 445 IU/L (normal, 45 to 420 IU/L). The he--patic synthetic function was intact as indicated by a normal serum al--bumin level and PT. An abdominal ultrasound showed normal hepatic morphology. Viral serologic tests were negative.
There was no history of using other drugs, no risk factors for ex--posure to parenterally transmitted viruses or other hepatotoxins, and no family history of liver disease. Montelukast was discontinued with the development of symptoms. AST, ALT, bilirubin, ALP, and glu--tamyltransferase levels normalized within two weeks. Montelukastinduced hepatitis was suggested by rapid improvement after dechal--lenge, the exclusion of other causes of hepatitis and by comparison with the reports of similar cases. A liver biopsy had not been done.
Using LTRA in the treatment and prophylaxis of allergic asthma in childhood is gradually becoming more prevalant. The side effects of montelukast have rarely been re--ported, except for sporadic cases of urticaria, angioedema, erythema nodosum, and Churge-Strauss syndrome in adults. 9, 10 One patient presented with pemphigus after using montelukast. 11 Recently, sev--eral cases of hepatotoxicity with zafirlukast and rarely, montelukast, were reported, but none included pediatric patients.
The mechanism of hepatotox--icity associated with LTRA is not clearly defined. Not infrequently drug-induced hepatotoxicity ap--pears after a latency period as long as 2 years, 7 but the reported cases related to montelukast and zafirlu--kast had latency periods between 5 to 24 months. 2, 3, 6, 7 This pattern may be similar to phenprocoumoninduced hepatitis, which has a la--tency period of typically 6 months and more. 7 This phenomenon is still not fully described. Besides this, other mechanisms of hepe--atotoxicity, like hepatotoxic metab--olites, idiosyncrasy, drug reactions and immunologic mechanisms are hypothesized. 2, 8 In liver biopsy, histological findings from previ--ously published reports described mild chronic inflammation in por--tal areas , without lobular inflama--tion or fibrosis. 8 Clinical trials of montelukast showed no significant difference in liver function abnormalities be--tween the montelukast group and the placebo group (2.1% of 1955 montelukast recipients had an in--creased ALT level vs. 2.0% of 1180 placebo recipients, and 1.6% of montelukast recipients developed self-limited, transient increases in AST levels vs. 1.2% of placebo re--cipients). 12 To our knowledge, this is the first reported case of druginduced hepatitis probably caused by montelukast in a child.
A review of all reported cases of leukotriene modifier-induced hepatitis revealed that hepatic tox--icity may develop within weeks or as late as 24 months after initiating therapy. 7, 8 With the increasing use of these drugs, which has coincided with monitoring of liver function, more asymptomatic cases may come on the scene. Because of their efficacy, convenient oral dosing and apparent safety, the LTRA, mon--telukast and zafirlukast, have be--come frequently prescribed drugs for the therapy of asthma. To date, serial liver function testing is not recommended for patients receiv--ing zafirlukast or montelukast, 2, 8, 13 but physicians should be aware of a potential hepatotoxic effect of montelukast, which may occur af--ter many months of drug initiation. Periodic screening of liver function tests seems like a more prudent ap--proach.
